Dosing

Not an actual patient
Convenient once-daily dosing

INGREZZA® (valbenazine) capsules—once-daily dosing without complex titration1

ONECAPSULE

The only VMAT2 inhibitor that offers the ease of one capsule, once daily1

TWOOPTIONS

Two dosing options that work1

Pills
  • VMAT2=vesicular monoamine transporter 2.
  • Not actual size.

INGREZZA is the MOST PRESCRIBED FDA-APPROVED TD treatment for adults2,a

  • a Data identified from Q2 2018 through Q1 2019.

Initial dosage of INGREZZA is 40 mg once daily for one week. After the first week, INGREZZA 80 mg is the recommended dose, but INGREZZA 40 mg may be considered for some patients1

  • Once on INGREZZA 80 mg, adjusting back to 40 mg may be considered based on your patient's individual treatment needs1
  • In clinical trials, investigators could decrease the 80 mg dose once at any time during the study due to tolerability. Participants were discontinued if the new dose was not tolerated3

In clinical trials, patients receiving INGREZZA were allowed to remain on their stable treatment regimen3

In KINECT 3, the most common types of concomitant medications were2,3

  • Antipsychotics (85.5%)
  • Antidepressants (66.5%)
  • Anticholinergics (37.0%)
  • Antiepileptics (35.2%)
  • Anxiolytics (27.7%)
  • ACE inhibitors (25.1%)

INGREZZA can be taken with or without food1

Drug interactions

Choose the appropriate INGREZZA® (valbenazine) capsules dose based on your patient’s needs1

Dosing recommendations for patients with complex medical histories1

Moderate to severe hepatic impairment Recommended dose 40 mg
Known CYP2D6 poor metabolizers Consider dose reduction based on tolerability
Strong CYP3A4 inducers Concomitant use not recommended
Strong CYP3A4 inhibitors Reduce dose to 40 mg
Strong CYP2D6 inhibitors Consider dose reduction based on tolerability
MAOIs Avoid concomitant use
Digoxin Digoxin concentrations should be monitored when coadministered; may need to adjust digoxin dosage
  • MAOIs, monoamine oxidase inhibitors.
In clinical trials, patients receiving INGREZZA were allowed to remain on their stable treatment regimen3
Administration information

INGREZZA® (valbenazine) capsules administration information

Continue to make monitoring a routine part of care for patients with tardive dyskinesia (TD)

Kidney icon

For TD patients with renal impairment1

Dosage adjustment is not necessary for patients with mild to moderate renal impairment (creatinine clearance 30-90 mL/min). INGREZZA does not undergo primary renal clearance. INGREZZA is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min).

Liver icon

For TD patients with hepatic impairment1

Dosage reduction of INGREZZA is recommended for patients with moderate or severe hepatic impairment (Child-Pugh score between 7 and 15). Patients with moderate to severe hepatic impairment had higher exposure of INGREZZA and its active metabolite than patients with normal hepatic function. The recommended dose for patients with moderate or severe hepatic impairment is INGREZZA 40 mg once daily.

Heart icon

For patients with increased cardiac risk1

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.